| 7521464 |
Pyrazole compounds for treatment of neurodegenerative disorders |
Yuhpyng L. Chen, Spiros Liras, Martin Patrick Allen |
2009-04-21 |
$587,839,000 |
| 7442702 |
Prostaglandin agonists |
Kimberly O. Cameron, Bruce Lefker |
2008-10-28 |
$154,383,000 |
| 7238721 |
Pyrazole compounds for treatment of neurodegenerative disorders |
Yuhpyng L. Chen, Spiros Liras, Martin Patrick Allen |
2007-07-03 |
$254,640,000 |
| RE39558 |
5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis |
Kimberly O. Cameron, Paul A. DaSilva Jardine |
2007-04-10 |
|
| 6998423 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
Kimberly O. Cameron, Hua Zhu Ke, Bruce Lefker, David Thompson |
2006-02-14 |
$991,144,000 |
| 6821989 |
Method of treating certain cancers using an estrogen agonist/antagonist |
— |
2004-11-23 |
$151,652,000 |
| 6756388 |
Benzothiophenes and related compounds as estrogen agonists |
Kimberly O. Cameron, Paul Da Silva-Jardine, Eric R. Larson, James R. Hauske |
2004-06-29 |
$204,847,000 |
| 6649657 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
Kimberly O. Cameron, Hua Zhu Ke, Bruce Lefker, David Thompson |
2003-11-18 |
$153,763,000 |
| 6632834 |
Compositions and methods for treating conditions responsive to estrogen |
David Thompson, Andrew Lee, Wesley Day |
2003-10-14 |
$299,772,000 |
| 6498172 |
Prostaglandin agonists and their use to treat bone disorders |
Kimberly O. Cameron, Bruce Lefker |
2002-12-24 |
$242,359,000 |
| 6492412 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
Kimberly O. Cameron, Hua Zhu Ke, Bruce Lefker, David Thompson |
2002-12-10 |
$251,101,000 |
| 6441193 |
Estrogen agonists/antagonists |
Kimberly O. Cameron, Paul DaSilva-Jardine, Hua Zhu Ke |
2002-08-27 |
$152,025,000 |
| 6426359 |
Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
Kimberly O. Cameron, Hua Zhu Ke, Bruce Lefker, David Thompson |
2002-07-30 |
$677,937,000 |
| 6376502 |
Osteoporosis compounds |
Kimberly O. Cameron, Bruce Lefker |
2002-04-23 |
$303,971,000 |
| 6288120 |
Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
Kimberly O. Cameron, Hua Zhu Ke, Bruce Lefker, David Thompson |
2001-09-11 |
|
| 6204286 |
Estrogen agonists/antagonists |
Kimberly O. Cameron, Paul A. DaSilva Jardine |
2001-03-20 |
$2,571,539,000 |
| 6153622 |
Estrogen agonists/antagonists |
Kimberly O. Cameron, Paul DaSilva-Jardine, Hua Zhu Ke |
2000-11-28 |
$1,018,671,000 |
| 6124314 |
Osteoporosis compounds |
Kimberly O. Cameron, Bruce Lefker |
2000-09-26 |
$342,922,000 |
| 5703108 |
Bone deposition by certain prostaglandin agonists |
Kimberly O. Cameron, Paul DaSilva-Jardine |
1997-12-30 |
$136,495,000 |
| 5552412 |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
Kimberly O. Cameron, Paul A. DaSilva Jardine |
1996-09-03 |
$55,270,000 |
| 5442044 |
Orally active renin inhibitors |
Dennis J. Hoover, Bruce Lefker |
1995-08-15 |
$22,385,000 |
| 5034376 |
Nor-statine and nor-cyclostatine polypeptides |
Dennis J. Hoover, Ronald T. Wester |
1991-07-23 |
$94,473,000 |
| 4992562 |
Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues |
Edward F. Kleinman, Jasjit S. Bindra |
1991-02-12 |
$10,228,000 |
| 4948913 |
Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues |
Edward F. Kleinman, Jasjit S. Bindra |
1990-08-14 |
$15,297,000 |
| 4935405 |
Nor-statine and nor-cyclostatine polypeptides |
Dennis J. Hoover, Ronald T. Wester |
1990-06-19 |
$10,742,000 |
